References
- Allen J E, Valeri R. Prostaglandins in hematology. Arch Intern Med 1974; 133: 86–96
- Bergström S, v. Duner H, Euler U S, Sjövall J. Observations on the effects of infusion of prostaglandin E in man. Acta Physiol Scand 1959; 45: 145–151
- Carlson L A, Ekelund L G, OrÖ L. Clinical and metabolic effects of different doses of prostaglandin E1 in man. Acta Med Scand 1968; 183: 423–430
- Fukui A, Maeda M, Mine T, Inada Y, Mizumoto S, Tamai S. Continuous local intraarterial infusion after prolonged arterial stasis in the fingers and toes. Microsurgery 1992; 13: 62–66
- Goto J, Araki H, Otomo S, Aihara H. A comparison of the effect of Lipo PGE1 and other related-compounds on.experimental peripheral arterial occlusive disease in rats. Drugs Exp Clin Res 1986; 12: 917–921
- Itaoka T, Iwai M, Koyama Y, et al. The effect of Lipo-Prostaglandin E1 on canine femoral arterial allografts. Transplant Proc 1992; 24: 1360–1362
- Katoh K, Kawai T, Narita M, Uemura J, Tani K, Okubo T. Use of prostaglandin E1 (lipo-PGE1) to treat Raynaud's phenomenon associated with connective tissue disease: thermographic and subjective assessment. J Pharm Pharmacol 1991; 44: 442–444
- Knight K R, Lepore D A, O'Brien B M. Interrelationship between prostanoids and skin flap survival: A review. Prostaglandins Leukot Essent Fatty Acids 1991; 44: 195–200
- Mizushima Y, Yanagawa A, Hoshi K. Prostaglandin E1 is more effective, when incorporated in lipid microspheres, for treatment of peripheral vascular diseases in man. J Pharm Pharmacol 1983; 35: 666–667
- Mizushima Y, Hamano T, Haramoto S, et al. Distribution of lipid microspheres incorporating prostaglandin E1 to vascular lesions. Prostaglandins Leukot Essent Fatty Acids 1990; 41: 269–272
- Mizushima Y, Shinokawa Y, Homma M, et al. A multicenter double blind controlled study of lipo-PGE1, PGE1 incorporated in lipid microspheres, in peripheral vascular disease secondary to connective tissue disorders. J Rheumatol 1987; 14: 97–101
- Morain W D, Pettit R J, Rothkopf D M, Coombs D W. Augmentation of surviving flap area by intraarterial vasodilators administered through implantable pumps. Ann Plast Surg 1983; 11: 46–52
- Ono I, Ohura T, Murazumi M, Sakamura R, Chiba S. A study on the effectiveness of a thromboxane synthetase inhibitor (OKY-046) in increasing the survival length of skin flaps. Plast Reconstr Surg 1990; 86: 1164–1173
- Piper P J, Vane J R, Wyllie J H. Inactivation of prostaglandins by the lungs. Nature 1970; 225: 600–604
- Sawada Y, Yotsuyanagi T, Hatayama I, Sone K. The relationship between prostaglandin E1 applied area and flap survival rate. Br J Plast Surg 1992; 45: 465–468
- Sekhar N C. Effect of eight prostaglandins on platelet aggregation. J Med Chem 1970; 13: 39–44
- Sim A K, McCraw A P, Cleland M E, Aihara H, Otomo S, Hosoda K. The effect of prostaglandin E1, incorporated in lipid microspheres on thrombus formation and thrombus disaggregation and its potential to target to the site of vascular lesions. Arzneimittelforschung 1986; 36: 1206–1209
- Suzuki K, Takahashi K, Matsuki Y, et al. Fluorescent probe-labeled lipid microsphere uptake by human endothelial cells: a flow cytometric study. Jpn J Pharmacol 1992; 60: 349–356
- Yamamoto Y, Ohura T, Nohira K, et al. Laserflowgraphy: A new visual blood flow meter utilizing a dynamic laser speckle effect. Plast Reconstr Surg 1993; 91: 884–894